ASX Filings

Opthea Presents Additional Data from Ph2b Trial at OIS in US

October 11, 2019

Opthea Presentation for Ophthalmology Innovation Summit

October 10, 2019

Change in substantial holding

October 9, 2019

Becoming a substantial holder

October 8, 2019

Ceasing to be a substantial holder

October 8, 2019

Opthea to Present at the Ophthalmology Innovation Summit in San Francisco

October 3, 2019

Additional Formats

PDF Version

Opthea Receives A$14.6m R&D Tax Incentive

October 1, 2019

Additional Formats

PDF Version

Appendix 3B

September 30, 2019

Change in substantial holding

September 13, 2019

Opthea Presents Positive Data from OPT-302 Phase 2b Wet AMD Trial at EURETINA Congress

September 6, 2019

Additional Formats

PDF Version